Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR)

被引：2
|
作者：
Ozaki, Y.
Kitano, S.
Matsumoto, K.
Takahashi, M.
Mukohara, T.
Futamura, M.
Masuda, N.
Tsurutani, J.
Yoshimura, K.
Minami, H.
Takano, T.
机构：
[1] Toranomon Gen Hosp, Tokyo, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[4] NHO Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Gifu Univ, Gifu, Japan
[7] NHO Osaka Natl Hosp, Osaka, Japan
[8] Kindai Univ, Osaka, Japan
[9] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[10] Kobe Univ, Sch Med, Kobe, Hyogo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT1-12-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-12-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).
    Ozaki, Yukinori
    Matsumoto, Koji
    Takahashi, Masato
    Mukohara, Toru
    Futamura, Manabu
    Masuda, Norikazu
    Tsurutani, Junji
    Yoshimura, Kenichi
    Minami, Hironobu
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2negative MBC in NEWBEAT trial (WJOG9917BTR)
    Ozaki, Yukinori
    Kitano, Shigehisa
    Tsurutani, Junji
    Iwasa, Tsutomu
    Takahashi, Masato
    Mukohara, Toru
    Masuda, Norikazu
    Futamura, Manabu
    Minami, Hironobu
    Matsumoto, Koji
    Kawabata, Hidetaka
    Yamashita, Makiko
    Yoshimura, Kenichi
    Takano, Toshimi
    CANCER RESEARCH, 2021, 81 (04)
  • [3] Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)
    Mukohara, Toru
    Ozaki, Yukinori
    Kitano, Shigehisa
    Yamashita, Makiko
    Ikarashi, Daiki
    Tsurutani, Junji
    Iwasa, Tsutomu
    Takahashi, Masato
    Masuda, Norikazu
    Futamura, Manabu
    Minami, Hironobu
    Matsumoto, Koji
    Tanabe, Yuko
    Kawabata, Hidetaka
    Yoshimura, Kenichi
    Takano, Toshimi
    CANCER RESEARCH, 2023, 83 (05)
  • [4] A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial
    Ozaki, Yukinori
    Mukohara, Toru
    Tsurutani, Junji
    Takahashi, Masato
    Matsumoto, Koji
    Futamura, Manabu
    Masuda, Norikazu
    Kitano, Shigehisa
    Yoshimura, Kenichi
    Minami, Hironobu
    Takano, Toshimi
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
    Tiainen, Leena
    Tanner, Minna
    Lahdenpera, Outi
    Vihinen, Pia
    Jukkola, Arja
    Karihtala, Peeter
    Paunu, Niina
    Huttunen, Teppo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
  • [6] Bevacizumab A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Croom, Katherine F.
    Dhillon, Sohita
    DRUGS, 2011, 71 (16) : 2213 - 2229
  • [7] Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
    Delaloge, S.
    Perol, D.
    Courtinard, C.
    Brain, E.
    Asselain, B.
    Bachelot, T.
    Debled, M.
    Dieras, V.
    Campone, M.
    Levy, C.
    Jacot, W.
    Lorgis, V.
    Veyret, C.
    Dalenc, F.
    Ferrero, J. M.
    Uwer, L.
    Kerbrat, P.
    Goncalves, A.
    Mouret-Reynier, M. A.
    Petit, T.
    Jouannaud, C.
    Vanlemmens, L.
    Chenuc, G.
    Guesmia, T.
    Robain, M.
    Cailliot, C.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1725 - 1732
  • [8] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
    Dieras, Veronique
    Pop, Simona
    Berger, Frederique
    Dujaric, Marie-Eglantine
    Beuzeboc, Philippe
    Escalup, Laurence
    Bidard, Francois Clement
    Cottu, Paul Henri
    Le Tourneau, Christophe
    Piperno-Neumann, Sophie
    Laurence, Valerie
    Robain, Mathieu
    Asselain, Bernard
    Pierga, Jean-Yves
    ANTICANCER RESEARCH, 2017, 37 (03) : 1403 - 1407
  • [9] Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)
    Ozaki, Yukinori
    Tsurutani, Junji
    Mukohara, Toru
    Iwasa, Tsutomu
    Takahashi, Masato
    Tanabe, Yuko
    Kawabata, Hidetaka
    Masuda, Norikazu
    Futamura, Manabu
    Minami, Hironobu
    Matsumoto, Koji
    Yoshimura, Kenichi
    Kitano, Shigehisa
    Takano, Toshimi
    EUROPEAN JOURNAL OF CANCER, 2022, 171 : 193 - 202
  • [10] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients
    Fabi, A.
    Russillo, M.
    Metro, G.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Giannarelli, D.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345